As a pharmacist, I want to add some clinical context to this discussion on Purchasing GLP-1 in Mexico September.
Building on what paige_pharma said — the evidence base here is robust. The key publications to reference are from the SUSTAIN program[1].
Key clinical points:
- Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
- Side effect profile is predictable and usually manageable with standard protocols
- Monitoring should include baseline labs and follow-up at 3-month intervals
- Patient education significantly improves outcomes and adherence
Standard disclaimer: this is educational, not individualized medical advice.
References:
[1] See thread title for relevant study identification.
Last edited: Sep 9, 2024 at 9:54 PM